4CPS-217 A comparative evaluation of the long-term effectiveness of guselkumab and risankizumab in the clinical management of plaque psoriasis

• Published in: European journal of hospital pharmacy. Science and practice Vol. 31; no. Suppl 1; pp. A156 - A157
• Main Authors: Rodriguez Goicoechea, M, Gutiérrez Lucena, L, Moreno Lopez, AJ, Cano Dominguez, S, Garrido Colmenero, C, Moreno Suarez, FG, Ocaña Cano, M, Aceituno, P, Tejedor Tejada, E, Horno Ureña, F
• Format: Journal Article
• Language: English
• Published: London British Medical Journal Publishing Group 20.03.2024; BMJ Publishing Group LTD
• Subjects: Conflicts of interest; Psoriasis; Section 4: Clinical pharmacy services
• ISSN: 2047-9956; 2047-9964
• DOI: 10.1136/ejhpharm-2024-eahp.321

Background and ImportanceAnti-interleukin 23 drugs were approved in the last 6 years. The absence of long-term comparison between alternatives such as risankizumab or guselkumab needs to be fulfilled.Aim and ObjectivesTo evaluate the effectiveness through indirect comparisons of risankizumab and guselkumab in plaque psoriasis long-term treatment.Material and MethodsMulticentric, retrospective and observational study. Comparison made with plaque psoriasis patients with active treatment with risankizumab or guselkumab to September 2023 overcoming 52 weeks of treatment. Demographic (sex, age) and clinical (psoriasis area severity index (PASI) at baseline and in subsequent dermatology controls, PASI clearance (PASI 90 and PASI100)) data collected. Comparison made through PASI90/PASI100 and PASI reduction.Results110 patients recruited for the study, with 35.5% of them being female and with an average age of 51.7 years. Initial PASI score was 9.46 for the 46 patients treated with guselkumab, and 8.04 for the 64 patients treated with risankizumab. The results are shown in the following tables: N PASI Averaged weeks PASI90 PASI100 46 (guselkumab) 1,12 62 60,8% 56,5% 64 (risankizumab) 0,88 63 68,75% 62,5% N PASI Averaged weeks PASI90 PASI100 23 (guselkumab) 0,94 114 69,5% 65,2% 30 (risankizumab) 0,89 110 63,3% 46,6% N PASI Averaged weeks PASI90 PASI100 15 (guselkumab) 2,61 150 60% 60% 18 (risankizumab) 0,7 136 72,2% 50% Conclusion and RelevanceBoth molecules offer highly positive long-term results, particularly valued by patients with plaque psoriasis, although guselkumab seems to maintain a slightly greater full clearance.References and/or AcknowledgementsArtificial intelligence tool utilised to translate texts.Conflict of InterestNo conflict of interest.